GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Debt-to-Revenue

ValiRx (LSE:VAL) Debt-to-Revenue : N/A (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

ValiRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.01 Mil. ValiRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was £0.01 Mil. ValiRx's annualized Revenue for the quarter that ended in Jun. 2024 was £0.00 Mil.


ValiRx Debt-to-Revenue Historical Data

The historical data trend for ValiRx's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Debt-to-Revenue Chart

ValiRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A 2.20

ValiRx Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 1.10 N/A

Competitive Comparison of ValiRx's Debt-to-Revenue

For the Biotechnology subindustry, ValiRx's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where ValiRx's Debt-to-Revenue falls into.


;
;

ValiRx Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

ValiRx's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.01 + 0.012) / 0.01
=2.20

ValiRx's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.01 + 0.007) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


ValiRx Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of ValiRx's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx Business Description

Traded in Other Exchanges
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.